BeOne Medicines Wins FDA Approval for Brukinsa Tablet Across All Five Indications
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
Vietnam-based Gene Solutions, a provider of genetic tests and non-invasive prenatal testing (NIPT) for women’s...
Suzhou-based MEI Medical Technologies Co., Ltd., a medical device manufacturer specializing in peripheral vascular intervention,...
US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK...
US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...
Shenzhen-based XtalPi Holdings Limited (HKG: 2228), an AI-driven pharmaceutical company, announced the complete acquisition of...
China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...
Dr. Cheng Kam-chung, Founder and Chairman of the Greater China Cancer Foundation (GCCF), led a...
Shenzhen-based ImmVira announced that it has administered the first patient dose in a global, multi-center...
Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a...
US-based Varian Medical Systems (NYSE: VAR) announced that it has received marketing approval from China’s...
Danish pharmaceutical giant Novo Nordisk’s (NYSE: NVO) China unit announced an organizational restructuring, merging its...
US-based Eli Lilly & Co. (NYSE: LLY) announced a global licensing and multi-target research collaboration...
Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for...
China’s National Medical Products Administration (NMPA) released the “Guidelines for Classification Definition of Next-Generation Sequencing...
Last month, China’s National Health Commission officially issued the Class 3 Hospital Accreditation Standards (2025...
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that Its wholly-owned subsidiary Hangzhou Zhongmei Huadong...
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that its core product Jiatailai (sacituzumab...
China’s Center for Drug Evaluation (CDE) released a draft guideline titled “Scope, Classification and Definitions...
Switzerland-based Philochem AG, a wholly-owned subsidiary of the Philogen Group (BIT: PHIL), announced a licensing...